Galmed Pharmaceuticals (GLMD) Total Liabilities (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Total Liabilities of $16.0 million for Q1 2026, down 14.22% year-over-year from $18.7 million in Q1 2025, and down 13.96% quarter-over-quarter from $18.6 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Total Liabilities (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Total Liabilities history runs 14 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 14.22% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 14.22% YoY), while the FY2025 annual figure was $18.6 million, up 2076.05% from the prior year.
- Total Liabilities for Q1 2026 stood at $16.0 million, down from $18.6 million in the prior quarter.
- The five-year high for Total Liabilities was $30.2 million in Q1 2022, with the low at $856000.0 in Q4 2024.
- The 5-year median for Total Liabilities is $17.6 million (2023), against an average of $16.9 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities plunged 96.05% in 2023, then jumped 2076.05% in 2025.
- Galmed Pharmaceuticals' Total Liabilities stood at $16.6 million in 2022, then rose by 0.41% to $16.6 million in 2023, then slumped by 94.85% to $856000.0 in 2024, then surged by 2076.05% to $18.6 million in 2025, then dropped by 13.96% to $16.0 million in 2026.
- Business Quant data shows GLMD's Total Liabilities at $16.0 million in Q1 2026, $18.6 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 10.03 Bn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | 16.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.03 Mn |
| Dec 31, 2025 | 18.63 Mn |
| Sep 30, 2025 | 21.58 Mn |
| Jun 30, 2025 | 22.94 Mn |
| Mar 31, 2025 | 18.68 Mn |
| Dec 31, 2024 | 856,000.00 |
| Sep 30, 2024 | 20.95 Mn |
| Jun 30, 2024 | 13.34 Mn |
| Mar 31, 2024 | 14.52 Mn |
| Dec 31, 2023 | 16.63 Mn |
| Sep 30, 2023 | 17.64 Mn |
| Jun 30, 2023 | 13.28 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 16.56 Mn |
| Sep 30, 2022 | 20.87 Mn |
| Jun 30, 2022 | 23.58 Mn |
| Mar 31, 2022 | 30.20 Mn |
| Dec 31, 2021 | 36.61 Mn |
| Sep 30, 2021 | 44.30 Mn |
| Jun 30, 2021 | 52.33 Mn |